Age-associated Memory Impairment
Conditions
Keywords
MITOCHONDRIAL BIOMARKERS, BRAIN METABOLISM, COGNITION
Brief summary
The goal of this randomized controlled double-blind parallel-group interventional trial is to evaluate the effects of dietary supplementation with molecular hydrogen and pyrroloquinoline quinone in elderly. The main questions it aims to answer are: (1) whether the supplementation affects biomarkers of mitochondrial function in serum, and (2) whether the supplementation affects cognition and brain metabolism. The participants will be subjected to take the dietary supplement during 6 weeks.
Interventions
DIETARY_SUPPLEMENTSupplement
Dietary supplement containing molecular hydrogen and pyrroloquinoline quinone
DIETARY_SUPPLEMENTPlacebo
Inert substance
Sponsors
University of Novi Sad, Faculty of Sport and Physical Education
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \> 65 years * MMSE scores ranged from 23-27 * Informed consent signed
Exclusion criteria
* Take part in exercise on a regular basis * Severe chronic disease and acute injuries * History of dietary supplement use during the past 4weeks * No consent to randomization * Participation in other studies
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Fibroblast growth factor 21 | Change from baseline serum fibroblast growth factor 21 at 6 weeks | Level of fibroblast growth factor 21 in serum |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Brain-derived neurotrophic factor | Change from baseline serum brain-derived neurotrophic factor at 6 weeks | Level of brain-derived neurotrophic factor in serum |
| Irisin | Change from baseline serum irisin at 6 weeks | Level of irisin in serum |
| Peroxisome proliferator-activated receptor gamma coactivator 1-alpha | Change from baseline serum peroxisome proliferator-activated receptor gamma coactivator 1-alpha at 6 weeks | Level of peroxisome proliferator-activated receptor gamma coactivator 1-alpha 21 in serum |
| Brain creatine | Change from baseline brain creatine at 6 weeks | MRS spectra for brain creatine |
| Brain oxygenation | Change from baseline brain oxygenation at 6 weeks | Near-infrared spectroscopy for prefrontal oxygen saturation |
| General cognition | Change from baseline MMSE score at 6 weeks | Mini-MentalStateExamination (MMSE) score |
Countries
Serbia
Outcome results
None listed